Sign In
Buy ZBIO
$17.40
+0.270 (+1.58%)
At Close: Jun 03, 2026
Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
07:00am, Monday, 16'th Mar 2026
- Obexelimab marketing applications for the treatment of IgG4-RD expected to be submitted to the FDA in Q2 2026 and the EMA in H2 2026 based on the Phase 3 INDIGO trial results - - Topline results of
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Friday, 20'th Feb 2026
WALTHAM, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Zenas BioPharma, Inc. (NASDAQ: ZBIO)
10:46am, Tuesday, 17'th Feb 2026
NEW YORK, Feb. 17, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Zenas BioPharma, Inc. (NASDAQ: ZBIO) on behalf of the company's shareholders. The investigation seeks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
06:56pm, Thursday, 12'th Feb 2026
NEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO). Such investors are advised to
- Obexelimab met the primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo over weeks 8 and 12 (p=0.0009) -
First Look: Lilly jumps; Novo warns; Walmart tops $1T
07:38am, Wednesday, 04'th Feb 2026
Stock News Lilly beats and lifts outlook: Eli Lilly (LLY) posted Q4 revenue of $19.29B (+43%) and adjusted EPS of $7.54, and guided 2026 revenue to $80â$83B a
Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
07:05am, Wednesday, 04'th Feb 2026
WALTHAM, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Receives Average Recommendation of “Moderate Buy” from Brokerages
05:00am, Wednesday, 04'th Feb 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO - Get Free Report) has received a consensus rating of "Moderate Buy" from the eight analysts that are covering the company, MarketBeat Ratings reports. One research
Market Today: Disney picks D'Amaro; PepsiCo trims prices
05:35pm, Tuesday, 03'rd Feb 2026
Guru Stock PicksT Rowe Price Equity Income Fund has made the following transactions:Reduce in MET by 1.04%Sold out in ADBEAdd in REXR by 1.73%New position in CO
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zenas BioPharma, Inc. – ZBIO
01:54pm, Tuesday, 03'rd Feb 2026
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. (“Zenas” or the “Company”) (NASDAQ: ZBIO). Such investors are
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Short Interest Up 27.4% in January
04:24am, Monday, 02'nd Feb 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO - Get Free Report) saw a significant growth in short interest in January. As of January 15th, there was short interest totaling 6,086,840 shares, a growth of 27.4%
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
10:00am, Thursday, 29'th Jan 2026
NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO). Such investors are advised to
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
01:22pm, Tuesday, 27'th Jan 2026
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. (“Zenas” or the “Company”) (NASDAQ: ZBIO). Such investors are
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
10:00am, Thursday, 22'nd Jan 2026
NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO). Such investors are advised to
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Friday, 16'th Jan 2026
WALTHAM, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader
